Clinical advancements in the field of urology are featured in the news media every day. This section provides patients and physicians with the most up-to-date information on recent urologic advancements around the world.
* Please Note - TUCC does not necessarily advocate any of the treatment methods listed in the articles below. This news feed is provided as a resource for those interested in the latest urologic research occurring around the world.
A new drug has been found superior to current treatments in slowing the growth of advanced kidney cancer in patients who became resistant to the first-line therapies that had kept it in check, according to results from a clinical trial led by Dana-Farber Cancer Institute.
Kidney stone disease is a complex disorder with a strong genetic component. We conducted a genome-wide association study of 28.3 million sequence variants detected through whole-genome sequencing of 2,636 Icelanders that were imputed into 5,419 kidney stone cases, including 2,172 cases with a history of recurrent kidney stones, and 279,870 controls.
For years, research on prostate cancer has sought an approach to screening that is more individualized than a one-size-fits-all measurement of the level of prostate-specific antigen in a man’s blood. These efforts are now paying off.
Smoking is a risk factor for biochemical recurrence of prostate cancer (PCa) following radical prostatectomy (RP), new study findings suggest.
If you're one of the nearly 3 million men currently living with a diagnosis of prostate cancer, listen up: A new study says what you eat makes a big difference as to how long you'll live with your cancer.
New research on kidney stone formation reveals that zinc levels may contribute to kidney stone formation, a common urinary condition that can cause excruciating pain. The research found that zinc may be the core by which stone formation starts.
When the United States Preventive Services Task Force (USPSTF) recommended against routine PSA screening for early detection of prostate cancer in May 2012, it caused a sea change in practice patterns among primary care physicians.
The impact of the recommendations had “a significant chilling effect,” said Sam Chang, MD, a professor of Urology at Vanderbilt University Medical Center, who moderated a panel discussion on the topic at the 2015 American Urological Association (AUA) Annual Meeting.
Obesity is more strongly associated with elevated prostate cancer (PCa) risk among African-American than non-Hispanic white men, according to a new study.
The finding is based on a prospective analysis of data from 22,673 non-Hispanic white (NHW) men and 3,398 African-American (AA) men who participated in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Study subjects had a median follow-up of 5.6 years, during which 1,723 were diagnosed with PCa.
An international team of scientists have revealed the genetic root of prostate cancers in individual men, demonstrating that tumors share common gene faults which could potentially offer new targets for treatment. Prostate cancer is the second most common cancer and second leading cause of cancer death in men.
The research, published in Nature, is part of the International Cancer Genome Consortium - a global project committed to revealing genetic changes driving prostate cancer using the most up-to-date gene-sequencing technology available.
Active surveillance is effective and yields good outcomes in patients with clinical stage I testicular cancer (CSI-TC) who underwent orchiectomy, according to a pair of studies published in the December and January issues of the Journal of Clinical Oncology.
“Most patients with CSI-TC are cured by orchiectomy alone,” wrote study authors led by Christian Kollmannsberger, MD, of the University of British Columbia in Vancouver. “With highly effective chemotherapy providing a safety net, ultimate cure rates approach 100% irrespective of the postorchiectomy strategy employed.” Thus, diminishing morbidities associated with treatment is a primary concern.
TUCC is contracted with all major insurance companies. We look forward to providing you with clinically advanced, compassionate urologic care.